OBJECTIVES: To evaluate the association between apolipoprotein E (apo E) epsilon4 and mortality, the population attributable risk for mortality with epsilon4, and relative contributions of cardiovascular disease (CVD) and Alzheimer's disease (AD). DESIGN: Population-based cohort study. SETTING: Community-based. PARTICIPANTS: Permanent residents of Cache County, Utah, aged 65 and older as of January 1, 1995. MEASUREMENTS: Participants were genotyped at the apo E locus using buccal-swab deoxyribonucleic acid. Cardiovascular health was ascertained using self- or proxy-report interviews at participants' residences. AD was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders criteria. Utah Department of Vital Statistics quarterly reports were reviewed to identify participants who died. RESULTS: Crude evaluations showed nonsignificantly greater risk of death for epsilon2/2 (hazard ratio (HR)=1.66, 95% confidence interval (CI)=0.92-2.76) and epsilon3/4 (HR=1.11, 95% CI=0.97-1.26) genotypes and significantly greater risk for epsilon4/4 (HR=1.48, 95% CI=1.09-1.96). After adjustment for age, age(2), sex, and education, risks increased to 1.98 (95% CI=1.08-3.35), 1.28 (95% CI=1.12-1.46), and 2.02 (95% CI=1.47-2.71), respectively, compared with epsilon3/3 genotypes. Adjustment for presence of any CVD did not change the risk of death for epsilon3/4 and epsilon4/4. Adjustment for AD reduced the risk of death for epsilon3/4 (HR=1.13, 95% CI=0.99-1.30) and epsilon4/4 (HR=1.59, 95% CI=1.15-2.14). The population attributable risk of death for epsilon3/4 and epsilon4/4 genotypes combined is estimated at 9.6%. CONCLUSION: These findings suggested that the epsilon2/2, epsilon3/4, and epsilon4/4 genotypes have greater early mortality risks. Further analyses showed that AD partially mediates the association between epsilon3/4, epsilon4/4, and death.
OBJECTIVES: To evaluate the association between apolipoprotein E (apo E) epsilon4 and mortality, the population attributable risk for mortality with epsilon4, and relative contributions of cardiovascular disease (CVD) and Alzheimer's disease (AD). DESIGN: Population-based cohort study. SETTING: Community-based. PARTICIPANTS: Permanent residents of Cache County, Utah, aged 65 and older as of January 1, 1995. MEASUREMENTS: Participants were genotyped at the apo E locus using buccal-swab deoxyribonucleic acid. Cardiovascular health was ascertained using self- or proxy-report interviews at participants' residences. AD was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders criteria. Utah Department of Vital Statistics quarterly reports were reviewed to identify participants who died. RESULTS: Crude evaluations showed nonsignificantly greater risk of death for epsilon2/2 (hazard ratio (HR)=1.66, 95% confidence interval (CI)=0.92-2.76) and epsilon3/4 (HR=1.11, 95% CI=0.97-1.26) genotypes and significantly greater risk for epsilon4/4 (HR=1.48, 95% CI=1.09-1.96). After adjustment for age, age(2), sex, and education, risks increased to 1.98 (95% CI=1.08-3.35), 1.28 (95% CI=1.12-1.46), and 2.02 (95% CI=1.47-2.71), respectively, compared with epsilon3/3 genotypes. Adjustment for presence of any CVD did not change the risk of death for epsilon3/4 and epsilon4/4. Adjustment for AD reduced the risk of death for epsilon3/4 (HR=1.13, 95% CI=0.99-1.30) and epsilon4/4 (HR=1.59, 95% CI=1.15-2.14). The population attributable risk of death for epsilon3/4 and epsilon4/4 genotypes combined is estimated at 9.6%. CONCLUSION: These findings suggested that the epsilon2/2, epsilon3/4, and epsilon4/4 genotypes have greater early mortality risks. Further analyses showed that AD partially mediates the association between epsilon3/4, epsilon4/4, and death.
Authors: Maria G Matera; Daniele Sancarlo; Francesco Panza; Carolina Gravina; Grazia D'Onofrio; Vincenza Frisardi; Grazia Longo; Luigi P D'Ambrosio; Filomena Addante; Massimiliano Copetti; Vincenzo Solfrizzi; Davide Seripa; Alberto Pilotto Journal: Age (Dordr) Date: 2010-04-20
Authors: May A Beydoun; Hind A Beydoun; Jay S Kaufman; Yang An; Susan M Resnick; Richard O'Brien; Luigi Ferrucci; Alan B Zonderman Journal: J Am Geriatr Soc Date: 2013-03-21 Impact factor: 5.562
Authors: Emilie T Reas; Gail A Laughlin; Jaclyn Bergstrom; Donna Kritz-Silverstein; Elizabeth Barrett-Connor; Linda K McEvoy Journal: Neuropsychology Date: 2019-02-07 Impact factor: 3.295
Authors: Konstantin G Arbeev; Svetlana V Ukraintseva; Liubov S Arbeeva; Igor Akushevich; Alexander M Kulminski; Anatoliy I Yashin Journal: Biogerontology Date: 2010-12-31 Impact factor: 4.277
Authors: Kathleen M Hayden; Sarah A Gaussoin; Jaimie C Hunter; JoAnn E Manson; Bonnie C Sachs; Aladdin H Shadyab; Hilary A Tindle; Yasmin Mossavar-Rahmani; Khyobeni Mozhui; Beverly M Snively; Stephen R Rapp; Susan M Resnick Journal: Int J Geriatr Psychiatry Date: 2019-08-22 Impact factor: 3.485
Authors: Melissa Lamar; Lei Yu; Leah H Rubin; Bryan D James; Lisa L Barnes; Jose Marcelo Farfel; Chris Gaiteri; Aron S Buchman; David A Bennett; Julie A Schneider Journal: Alzheimers Dement Date: 2018-10-12 Impact factor: 21.566
Authors: Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman Journal: N Engl J Med Date: 2009-07-16 Impact factor: 91.245
Authors: Thomas O Obisesan; Robert E Ferrell; Andrew P Goldberg; Dana A Phares; Tina J Ellis; James M Hagberg Journal: Metabolism Date: 2008-12 Impact factor: 8.694